TYPLEX® Chelate, a novel feed additive, inhibits Campylobacter jejuni biofilm formation and cecal colonization in broiler chickens

Khattak, FM; Paschalis, V; Green, M; Houdijk, JGM; Soltanas, P; Mahdavi, J

Published in:
Poultry Science

DOI:
10.3382/ps/pex413

First published: 01/04/2018

Document Version
Peer reviewed version

TYPLEX® Chelate inhibits *Campylobacter Jejuni* Biofilm Formation and Caecal Colonization in Broiler Chickens

Farina Khattak*[1], Vasileios Paschalis[†], Matthew Green[†], Jos Houdijk*, Panos Soultanas†[1] and Jafar Mahdavi[†1]

*Monogastric Science Research Centre, Scotland Rural College (SRUC), Ayr, KA6 5HW, Scotland, UK.

[†]School of Chemistry, Centre for Biomolecular Sciences, University of Nottingham, NG7 2RD, UK.

Scientific section for paper: Microbiology and Food Safety

[1] Joint corresponding authors: farina.khattak@sruc.ac.uk or jafar.mahdavi@nottingham.ac.uk or panos.soultanas@nottingham.ac.uk

TYPLEX® Chelate inhibits *Campylobacter Jejuni* Biofilm Formation and Caecal Colonization in Broiler Chickens

ABSTRACT

Reducing *Campylobacter* spp. carriage in poultry is challenging, but essential to control this major cause of human bacterial gastroenteritis worldwide. Although much is known about the mechanisms and route of *Campylobacter spp.* colonization in poultry the literature is scarce on antibiotic-free solutions to combat *Campylobacter* spp. colonization in poultry. I*n vitro* and *in vivo* studies were conducted to investigate the role of TYPLEX® Chelate (ferric tyrosine), a novel feed additive, in inhibiting *Campylobacter jejuni* (*C. jejuni*) biofilm formation and reducing *C. jejuni* and *Escherichia coli* (*E. coli*) colonization in broiler chickens at market age. In an *in vitro* study, the inhibitory effect on *C. jejuni* biofilm formation using a plastic bead assay was investigated. The results demonstrated that TYPLEX® Chelate significantly reduces biofilm formation. In an *in vivo* study, 800 broilers (one-day old) were randomly allocated to 4 dietary treatments in a randomised block design, each having 10 replicate pens with 20 birds per pen. At day 21, all birds were challenged with *C. jejuni* via seeded litter. At day 42, caecal samples were collected and tested for volatile fatty acid (VFA) concentrations, *C. jejuni* and *E. coli* counts. The results showed that TYPLEX® Chelate reduced the carriage of *C. jejuni* and *E. coli* in poultry by 2 and 1 $\log_{10}$ per gram caecal sample, respectively, and increased caecal VFA concentrations. These findings support TYPLEX® Chelate as a novel non-antibiotic

feed additive that may help produce poultry with a lower public health risk of *Campylobacteriosis*.

KEY WORDS

Campylobacter**,** biofilm, volatile fatty acid, feed additive, food safety

INTRODUCTION

Campylobacter spp. infections are a major cause of human bacterial gastroenteritis and pose a serious health burden worldwide, accounting for 400-500 million cases of diarrhoea each year (Ruiz-Palacios, 2007). A significant proportion of health care costs are associated with sequelae linked to *Campylobacteriosis* such as Guillain-Barré syndrome, reactive arthritis and irritable bowel syndrome (WHO, 2013). Despite several government programs and awareness campaigns to reduce *Campylobacter* spp. little reduction is reported in the numbers of bacterium in animals and/or animal products in retail outlets (Robyn et al., 2015). It is estimated that foodborne transmission contributes to 58% of the global disease burden (Hald et al., 2015).

Chicken, pork and beef are reported as significant foodborne sources of *Campylobacter* with presence of the pathogen at high concentrations found throughout the food chain (Miller and Mandrell, 2005). The strong adhesion capability of *Campylobacter* strains could partly explain the rapid cross-contamination or re-contamination of food products, and may be the most significant mode of survival for *Campylobacter* in the food chain (Sulaeman et al., 2010).

Campylobacter infection is dependent on motility mediated by polar flagella A (**FlaA**) and adhesion and biofilm promoting ability of the Major Outer Membrane Protein (**MOMP**) (Ashgar et al., 2007; Muller et al., 2007 and Min et al., 2009; Mahdavi et al., 2014). Considering such idiosyncrasy, it is easy for *Campylobacter* to

colonize live animals and survive transitionally in the food chain or in biofilms before reaching the intestinal tract of humans (Buswell et al., 1998; Trachoo and Frank, 2002; Miller and Mandrell, 2005; Lehtola et al., 2006; Sanders et al., 2008).

Biofilms are accumulations of microorganisms embedded in an extracellular matrix (**ECM**) which adheres to solid biological or non-biotic surfaces (Costerton, 1995; Kalmokoff et al., 2006). The ECM comprises proteins, polysaccharides, nucleic acids and phospholipids (Stoodley et al., 2004). Foodborne bacterial pathogens can either form biofilms on inert surfaces or can reach and integrate into pre-established biofilms.

Increase in caecal volatile fatty acid (VFA) concentrations, indicating fermentation by anaerobic bacteria, are found to be negatively correlated with the number of Enterobacteriaceae in broiler chickens (Van Der et al., 2000; Kubena et al., 2001). Several strategies such as reduction of environmental exposure to *Campylobacter* by hygiene and biosecurity measures, water treatment, use of plant-derived feed additives, use of bacteriophage, bacteriocin therapies, vaccination, passive immunization, use of pre- and probiotics and genetic selection have been investigated to control on-farm *Campylobacter* contamination (Sahin et al., 2003; Chaveerach et al., 2004; Carrillo et al., 2005; Calderon-Gomez et al., 2009; Lin, 2009; Buckley et al., 2010; Svetoch and Stern, 2010; Hermans et al., 2010; Hermans et al., 2011). Despite all these efforts *Campylobacter* remains a major cause of human gastroenteritis and a priority for the development of new control strategies. In addition, use of antibiotics in both animal and human medicine can influence the development of antibiotic–resistant *Campylobacter* and is increasingly becoming a challenge for food safety and public health (Luangtongkum et al., 2009). The authors postulated that the novel feed additive, TYPLEX® Chelate, a synthetic complex of $_{L}$-

tyrosine and Fe (III), exerts a unique action on enteropathogens by preventing the formation of biofilms at chyme/mucosal and other interfaces. Based on the non-antimicrobial nature of ferric tyrosine the current studies were designed to demonstrate that TYPLEX® Chelate inhibits *C. jejuni* biofilm formation (*in vitro*), increases caecal VFA concentrations (*in vivo*) and thus has an ability to reduce caecal colonization of *C. jejuni* and *E. coli* in broilers at slaughter.

MATERIALS AND METHODS

Feed additive

TYPLEX® Chelate (Akeso Biomedical, Inc., Waltham, MA), a complex containing tyrosine and iron (ferric tyrosine), was the novel feed additive used in these studies.

Experimental diets

Basal iso-nitrogenous and iso-energetic wheat-soyabean meal control diets (T_1) were manufactured as one batch for each feeding phase *i.e.* starter (day 0-21) and grower (day 21-42). Three additional treatments (T_2 to T_4) were generated by addition of TYPLEX® Chelate to T_1 at 0.02, 0.05 and 0.20 g/kg feed, respectively. Diets were manufactured with coccidiostats but contained no veterinary antibiotics. The ingredients, premixes and the calculated analyses of the starter and grower diets are presented in Table 1. Diets were analysed for dry matter, nitrogen, ether extract and iron. Total nitrogen content of diet was determined by the combustion method (AOAC Method 968.06) whereas ether extract was determined in a soxhlet extractor (AOAC Method 922.06). Iron content was determined using Inductively Coupled Plasma – Optical Emission Spectroscopy (AOAC Method 990.08) following digestion, in turn, in concentrated Nitric and Hydrochoric acid. Coloured tracers (Micro-Tracers Inc, San Francisco) were added to TYPLEX™ chelate at 10% w/w, to

enable visual confirmation of TYPLEX™ chelate content and uniform mixing in feed samples.

In vitro assessment of C. jejuni biofilm inhibition in a simulated gut environment using a plastic bead assay

A plastic bead assay (O'Toole and Kolter, 1998; Stepanovic et al., 2000) with some modifications for suitability with *C. jejuni* was carried out *in vitro* to show that the TYPLEX® Chelate extracted from the experimental diets has an inhibitory effect on *C. jejuni* biofilm formation.

Extraction of TYPLEX® chelate from the experimental diets. 10 g aliquots of feed from all experimental diets (T_1 to T_4) for each phase were homogenised to very fine particles (around 100 µm) and mixed with 50 ml (1:5) of buffer (20 mM KCl/HCl; pH 3.4). The feed/buffer mixtures were autoclaved (high-pressure saturated steam at 121°C for around 15–20 minutes, 3 cycles). The high heat and pressure of the autoclave resulted in extraction of the TYPLEX® Chelate from the feeds while retaining its physical properties. The resulting suspensions were then filtered using filter paper (25 µm filter). The pH of all filtered samples was measured and found to be between 6.2 to 6.5.

Bead Assay. *C. jejuni* strain NCTC11168 was grown overnight in 3 ml of sterile brain heart infusion (**BHI**) broth under microaerophilic conditions (85% nitrogen, 10% carbon dioxide and 5% oxygen) at 42°C on modified *Campylobacter*-selective charcoal cefoperazone desoxycholate (**CCDA**). The optical density at a wavelength of 600 nm ($\mathbf{OD_{600}}$) of these cultures were measured, then they were used to inoculate a feed extract + BHI suspension (1:4 dilution) to achieve a final OD_{600} of 0.02.

Two sterile plastic beads per dietary treatment were placed into 2.5 ml of BHI, with 0.5 ml of the extracted feeds and inoculated with *C. jejuni*. The beads were then incubated at 42°C for 48 hr. Following incubation, the beads were gently washed twice (5x dipping each) in phosphate buffered saline (**PBS**), placed into 1 ml of PBS and vigorously vortexed for 30 s prior to centrifuging at 3000 rpm. The PBS containing bacterial cells released from the biofilm was serially diluted and 3 x 5 µl aliquots of each dilution were spotted onto **CCDA** agar plates for quantification (Thermo-Fisher plates, 3 plates/bead, two beads/treatment, 6 samples/treatment). The plates were subsequently incubated microaerophilically at 42°C for 48 hrs and colonies were counted and expressed as cfu/ml. The same experiment was carried out in triplicate.

Seeder litter challenge to colonise chicken with C. jejuni in vivo

To confirm *in vitro* findings, an *in vivo* study was designed to investigate the efficacy of TYPLEX® Chelate under farm conditions. A total of 800 male broiler chickens (Ross 308) were allocated randomly to pens in 4 dietary treatments (T_1 to T_4), with pens distributed using a randomized complete block design. Each treatment had 10 replicate floor pens with 20 chicks per pen. Birds were reared on fresh wood shavings in clean pens having European Union maximum stocking density at 42 d of 38 kg/m^2. At 21 days of age all birds were challenged with *C. jejuni* seeded litter. Diets were fed *ad libitum* for 42 days in mash form; body weight and feed intake of each replicate pen were recorded to calculate the global zootechnical data (days 0-39). At the end of the study (day 42), all birds were humanely killed through cervical dislocation and caecal samples were collected from 10 birds/pen and used for *C. jejuni* and *E. coli* enumeration, and 2 birds/pen for caecal VFA analysis.

167 The *in vivo* study (AU AE 37-2016) was carried out under the Animals Scientific
168 Procedures Act (1986) and approved by the ethical review committee of Scotland's
169 Rural College (SRUC).

170 ***Seeded litter challenge procedure.*** Approximately 20 kg of used poultry litter
171 was taken from a recently completed broiler study. The litter (not tested for any
172 pathogen) was placed in an oven at 80°C until a constant weight was obtained, then
173 divided into 400 g batches in forty trays (each tray was approximately 38 × 28 × 8
174 cm). Each dried reused litter tray was reconstituted with 1000 ml of deionised water.
175 Trays were then seeded with a mixture of Mueller-Hinton (**MH**) broth,
176 *Campylobacter* suspension (4.5 x 10^5 cfu *C. jejuni*/ml) and dried hen droppings (20
177 ml: 10 ml: 10g). The hen droppings were dried in the same way as the litter.
178 *Campylobacter* isolates were obtained from caecal samples taken from three different
179 commercial poultry farms and stored at -80°C in bead cryopreservation vials
180 (Technical Service Consultants, UK). *C. jejuni* (individual strains were not identified)
181 were resuscitated on Blood Agar No. 2 with Horse Blood (BA) plates (Oxoid, UK).
182 These cultures were used to prepare lawn plates on further BA plates, incubated for
183 40 – 48 hrs at 41.5°C, in boxes with a microaerophilic atmosphere generation system
184 (CampyGen, Oxoid, UK). The lawn plates were harvested by adding 5 ml MH broth,
185 gently detaching the culture with a sterile spreader and decanting to a container. The
186 suspension was then adjusted with further MH broth to OD_{600} of 0.19 – 0.21
187 (approximately 1.5 × 10^5 cfu.ml^{-1}). The bacterial suspension, broth and droppings
188 were mixed and spread evenly on the top of the litter tray. The tray was then placed in
189 a pen near the feeder.

190 ***Isolation and enumeration of C. jejuni from caeca.*** A sterile scalpel was used
191 to cut off the blind end of both caecal sacks from each chicken. For each sample, 0.5g

of content from each caecal sac (in total 1g) was weighed out into sterile Universal bottles. At each sampling, a total of 2g caecal content was diluted with 4 ml of sterile Maximum Recovery Diluent (**MRD**), which was added to each Universal container and mixed thoroughly. This constituted the 1:2 dilutions (w/v). A further 8 serial dilutions were made in MRD. Then, 5-10 µL of each dilution was spotted on CCDA, MRS, Brilliance or chromogenic plates (Oxoid PO0119) and left to dry. Plates were incubated microaerophilically at 41.5°C ± 2.0°C for 24-48 hrs. Following incubation, plates were assessed for the presence or absence of thermotolerant *Campylobacter* species. In addition, plates of an appropriate dilution level were selected and colonies enumerated. As a confirmatory measurement, two colonies from each presumptively positive plate were selected and sub-cultured onto paired blood agar plates (Oxoid PB0114). These plates were incubated at 37°C for 48 hrs, one plate aerobically and one plate microaerophilically. The presence of *C. jejuni* was indicated by lack of growth aerobically and colonies with *Campylobacter* morphology that grew microaerophilically. In addition, Gram stains were performed on all presumptively *Campylobacter* positive samples. Oxidase strips (Oxoid MB0266) were used to further confirm that the samples were oxidase positive.

In case of pre-inoculation testing, at day 16 cloacal swab (1 bird/pen) and overshoes (1 overshoe/pen) were tested for presence and absence of *C. jejuni* using the same procedure as reported for *C. jejuni* enumeration.

***Caecal volatile fatty acid analysis*.** The caecal digesta were gently flushed out in 30 ml universal sample containers and immediately stored at -80ºC until analysed. Samples were ground in the presence of solid CO_2 to ensure homogeneity. They were then shaken with a known volume of water to extract the fatty acids. The extracts were spiked with 4-methylvaleric acid as an internal standard and then passed to the

Gas Chromatography (HP 5890 Series II GC; Agilent J & W 30m × 0.535mm × 1.00 micon HP-FFAP column; FID detector) to determine the individual component composition by comparison with a series of standard solutions which were also spiked with an internal standard. Acetic, *n*-butyric, propanoic, n-valeric, *iso*-butyric and *iso*-valeric acid were detected and results were expressed as mg/kg.

Statistics

For the *in vitro* tests, a single 5 µl aliquot extracted from a bead in a serially-diluted manner, grown on a CDDA plate was the statistical unit of measurement. A randomized complete block design with ten blocks and four treatments was used for *in vivo* studies. The individual bird sampled was the experimental unit for microbiological (*C. jejuni* and *E. coli*) and VFA analysis whereas the pen was the experimental unit for growth performance data. The microbiological data were $\log_{10}$ transformed prior to analysis. Data obtained were subjected to Analysis of Variance (ANOVA) using a GenStat 16 statistical software package (IACR, Rothamstead, Hertfordshire, UK). Significance between treatments was determined using orthogonal polynomial contrasts. Where correlations are presented (identified using Genstat), all r^2 are significant to at least $P < 0.05$ unless otherwise stated. All statements of significance are based on the probability level of $P \leq 0.05$.

RESULTS

Nutrient composition and analysed TYPLEX® Chelate of the experimental diets were within the expected range and are presented in Tables 1 and 2 respectively.

Inhibitory impact of extracted TYPLEX® Chelate from feeds on C. jejuni biofilm formation

In vitro data showed that the addition of TYPLEX® Chelate significantly reduced the ability of *C. jejuni* to adhere to plastic beads and form a biofilm (Table 3). For the

starter diet, the addition of TYPLEX® Chelate extract at all concentrations reduced linearly the number of *C. jejuni* cells compared to the control group (0.5, 0.3 and 0.5 log_{10} cfu/g reduction**,** respectively, $P < 0.001$). Similar results were observed for the grower diet; the addition of TYPLEX® Chelate extract at 0.02 g/kg, 0.05 g/kg and 0.2 g/kg reduced linearly the number of *C. jejuni* cells compared to the control group (0.4, 1.4 and 1.0 log_{10} cfu/g reductions**,** respectively, $P < 0.001$).

Campylobacter infection and bird performance

The seeded litter challenge model was successful in horizontal transfer of *C. jejuni* in birds within pens. Pre-inoculation cloacal swabs and samples cultured from overshoes were negative, whereas all caecal samples from all pens cultured positive for *C. jejuni*. The growth performance of birds during the starter (days 0-21), grower (days 21 to 39) and overall growth period (days 0 to 39) is presented in Table 4. During the pre-challenge (starter phase), average weight gain (AWG) of all birds fed the TYPLEX® Chelate supplemented diet were consistently higher compared to the T1control group ($P < 0.05$). However, the differences were only significant when birds fed T2 and T4 (0.02 and 0.20g/kg TYPLEX® Chelate) were compared with T1 ($P < 0.05$). This improvement in AWG also resulted into 3.6% lower ($P < 0.05$) mortality adjusted feed conversion ratio (FCR) values compared with T1. During the *Campylobacter* challenged period (grower phase) all birds fed TYPLEX® Chelate (T2, T3 and T4) had 19.6% higher ($P < 0.05$) AWG compared to T1 (control group). This increase in AWG was also translated into 5.7% improvement in FCR of all birds fed TYPLEX® Chelate (T2, T3 and T4) supplemented diets compared to control group (T1). The average feed intake (AFI) over the entire trial period was lower ($P < 0.05$) for T3 (0.05g/kg TYPLEX® Chelate) compared to T1 control. This shift in AFI resulted in significantly lower ($P < 0.05$) FCR for birds in T3 group compared to

control. The overall growth performance depicted similar trends and showed 2.9 and 4.9% linear improvement ($P < 0.05$) in AWG in birds fed T2 and T3 (0.02 and 0.20g/kg TYPLEX® Chelate), respectively and 4.1 % lower ($P < 0.05$) FCR for birds fed all TYPLEX® Chelate diets (T2, T3 and T4) compared to control (T1). The overall AWG and FCR values were positively correlated (r^2 = 0.693, 0.822 respectively; $P < 0.05$) whereas, AFI showed no correlation ($r^2 = 0.03$; $P > 0.05$) with the inclusion level of TYPLEX® Chelate in the diet. The birds remained healthy through out the experimental period, and the percentage mortality for treatment 1 to 4 was 6.0, 6.5, 3.5 and 6.5% respectively. Mortality was not associated with treatment ($P > 0.05$).

Effect of TYPLEX® Chelate on caecal C. jejuni and E. coli colonization. Microbiological analyses of caecal samples showed a 0.8, 2.1 and 2.1 log10 cfu/g linear reduction ($P < 0.05$) in *C. jejuni* colonization in TYPLEX® Chelate supplemented T2, T3 and T4 treatment groups respectively compared to T1 control (Table 5). Similarly, 0.6, 0.8 and 1.2 $\log_{10}$ cfu/g linear reduction ($P < 0.05$) in *E. coli* counts was recorded in birds that received 0.02, 0.05 and 0.20 g/kg TYPLEX® Chelate (T2, T3 and T_4) compared with T1 control (Table 5). The *Campylobacter* spp. and *E. coli* counts were positively correlated with the inclusion level of TYPLEX® Chelate (r^2 = 0.931, 0.952, respectively; $P < 0.05$).

Effect of dietary TYPLEX® Chelate on caecal VFA concentrations. Individual and total VFA concentrations in the caecal digesta are presented in Table 6. Total VFA concentrations increased by 31 and 26% ($P < 0.05$) in birds fed 0.02 and 0.05 g TYPLEX® Chelate /kg feed, respectively, compared to the control group. This increase was due to a general increase in most acids. Thus, feeding birds diets containing 0.02 and 0.05 g TYPLEX® Chelate/kg feed increased ($P < 0.05$) the

292 concentration of acetic acid by 26 and 24 %, respectively, compared to the non-
293 supplemented T1 control. No additional increase in acetic acid concentration was
294 observed when the inclusion rate of TYPLEX® Chelate was further increased from
295 0.05 to 0.20 g/kg feed. Propionic acid concentrations were also consistently higher in
296 birds fed TYPLEX® Chelate diets, but the differences were not significant ($P > 0.05$)
297 when compared with the T1 control. Differences in the concentration of n-butyric acid
298 were more profound and the concentration linearly increased ($P < 0.05$) by 75, 66 and
299 41% in birds T2, T3 and T4 fed diets containing 0.02 and 0.05 and 0.20g TYPLEX®
300 Chelate /kg feed, respectively, compared with T1control . Also, n-valeric, *iso*-butyric
301 and *iso*-valeric acids were produced in very small quantities, but followed the same
302 trend, with significantly greater concentrations in birds fed T3 diets containing 0.05g
303 TYPLEX® Chelate/kg feed compared to T1 control.

304 **DISCUSSION**

305 The public health significance of *C. jejuni* infection and emergence of multi-antibiotic
306 resistant species of *Campylobacter* demands development of new control strategies in
307 addition to farm biosecurity measures to lower carriage of *C. jejuni* in live animals.
308 To our knowledge, this is the first study to report that TYPLEX® Chelate inhibits *C.*
309 *jejuni* biofilm formation. The *in vitro* assay showed that TYPLEX® Chelate (extracted
310 from experimental diets) in a simulated gut environment reduced the ability of *C.*
311 *jejuni* to adhere to plastic beads and form a biofilm.
312 It is known that MOMP binds to multiple host cell membranes by promoting biofilm
313 formation and auto-aggregation. It is the biofilm-forming ability of *C. jejuni* that
314 enables the organism to survive in the environment and enter the food chain (Joshua
315 et al., 2006). Based on our *in vitro* results it is likely that TYPLEX® Chelate inhibits
316 FlaA and MOMP-mediated adhesion of *C. jejuni* as evidenced by the reduction in

biofilm formation. The ability of *C. jejuni* to attach to surfaces and grow in biofilms, where they are protected from antibiotics, biocides, and other chemical or physical challenges, is a key factor in persistence of infection in humans (Costerton et al., 1999; Stewart, 2002; Stoodley et al., 2004). As the TYPLEX® Chelate inhibits biofilm formation it can therefore be helpful in farming and food processing to reduce cross-contamination of food products. This strategy offers an antibiotic-free method which will not encourage the emergence of resistance in pathogenic bacteria within the host organism. The inhibitory effect of TYPLEX® Chelate on biofilm formation showed the same pattern in starter and grower diets.

The birds in the current study were challenged at day 21 because *Campylobacter* spp. is rarely detected in commercial flocks of less than 3 weeks of age, regardless of production methods (Kazwala et al., 1990), species (Allen et al., 2011; Umar et al., 2016) and biosecurity measures (Allain et al., 2014). The lag phase in colonization of poultry, even in the presence of positive birds suggests that a biological mechanism of colonisation resistance may be present in young birds due to maternal antibodies (Cawthraw and Newell, 2010). The relatively dry litter in the poultry house may also limit the ability of *Campylobacter* to survive in the small volume of excreta produced by birds in the first few weeks of life (Sparks, 2016). However, when the flock is infected, the majority of birds become colonized within 4 to 7 days after infection of the first bird (Sahin et al., 2015), and the overall prevalence rises as high as 100% at slaughter age (Barrios et al., 2006), without any apparent clinical manifestations in the chicken host (Kaino et al., 1988).

The incidence of human campylobacteriosis is often associated with consumption of poultry products contaminated with *C. jejuni* and this, in turn, is linked to the number of *C. jejuni* present in the caeca of the bird (Wagenaar et al, 2006; Neal-McKinney et

342 al., 2014). As few as 500 cells of C. *jejuni* can cause infection (Black et al., 1988).
343 There is no evidence for a "safe" level of *Campylobacter* contamination, as the
344 minimum infectious dose will always be strain-specific. In general, it is considered
345 that the risk of *Campylobacteriosis* increases as the number of *Campylobacter* on the
346 bird increases (EFSA, 2009). Therefore, it is possible to reduce the incidence of
347 human infection by lowering the number of *C. jejuni* in birds bound for the food
348 supply. In this study, use of TYPLEX® Chelate in broiler diets at 0.05 and 0.20 g/kg
349 feed reduced the counts of caecal *C. jejuni* by up to 2 $\log_{10}$ cfu/g sample the counts of
350 caecal *C. jejuni* in broilers aged 42 days. According to food safety risk analysis
351 studies, this level of reduction in colonization may be able to reduce the public health
352 risk associated with human campylobacteriosis (Rosenquist et al., 2003; EFSA, 2011).
353 One of the mechanisms known to reduce *Enterobacteriaceae* (Gram-negative
354 bacteria) in the intestinal microflora is the bacteriostatic effect of VFA's in the caeca
355 (Van Der et al., 2000). The current study showed that feeding broilers with diets
356 supplemented with 0.02 and 0.05g TYPLEX® chelate/kg feed resulted in increased ($P < 0.05$)
357 caecal concentrations of total VFA, mainly due to higher production of acetic
358 and *n*-butyric acid. High concentrations of VFA are indicative of fermentations by
359 obligate anaerobic bacteria, reported to be an important source of energy for
360 enterocytes and vital for intestinal health (Sunkara et al., 2012). It has been reported
361 that increased concentrations of VFAs lower the intestinal pH, which is associated
362 with suppression of pathogens (Kubena et al., 2001, Rehman et al., 2007). VFAs not
363 only affect host functions but also serve as a carbon source for the endogenous
364 bacteria and at high concentrations can exhibit toxic effects on bacteria. Chickens are
365 omnivores, and the diversity of microbial communities in their intestinal tracts is
366 related to their life-style. It has been proposed that the different nutritional

requirements for maintaining homeostasis of the microbiota communities in the gut would be due to different fermentable substrates available in the terminal ilea (Fang et al., 2012). Among the bacterial fermentation end-products in the chicken caecum, butyrate is of particular importance because of its nutritional properties for epithelial cells and pathogen inhibitory effects in the gut (Sun and O'Riordan, 2013). In the current study, the reduction in the proportion of acetic, butyric and valeric acids in the challenged unsupplemented control group (T1) could be due to *C. jejuni*. It has been reported that *Campylobacter* colonization reduces butyrate, iso-butyrate, valerate, and iso-valerate in the caecum (Awad et al., 2016).

Furthermore, translocation of *E. coli* to the liver, spleen and caecum increases in birds infected with *C. jejuni* (Awad et al., 2016). Results from some of the epidemiological studies also reported an increase of *E. coli* in chicken carcasses that were infected with *Campylobacter* (Duffy et al., 2014). The results from this study suggest that *Campylobacter* infection may have an influence on the development of other microbial populations, such as *E. coli*, illustrated by the data on TYPLEX® Chelate, used at higher doses. At 0.20 g/kg feed, TYPLEX® Chelate not only caused a 2.1 $\log_{10}$ cfu/g reduction in caecal *C. jejuni* colonization but also resulted in 1 2 $\log_{10}$ cfu/g reduction in *E. coli* populations. In a previous study, we found that inclusion of TYPLEX® Chelate in broiler diets without coccidiostats caused a significant reduction in coccidial oocyst counts and elevated the microbial dominance at 52-54% Guanine + Cytosine in comparison with non-supplemented diets, indicative of high-performing healthy birds (Khattak et al., 1997). These results support the notion that TYPLEX® Chelate may reduce the activities of pathogenic bacteria but favour beneficial bacteria and thus enhance growth performance. In addition, the assessment of minimum inhibitory concentrations (**MIC**) of TYPLEX® Chelate to *C. jejuni*, *E.*

392 *coli*, and *Salmonella enterica* showed *that* TYPLEX® Chelate did not inhibit the
393 growth of these pathogens (personal communications with Dr Juha Apajalahti;
394 Alimetrics Group Ltd). The MIC values were higher than 400mg/l for *C. jejuni* and
395 higher than 200mg/l for *E. coli* and *Salmonella*, indicating that none of the enteric
396 pathogens tested were inhibited by TYPLEX® Chelate at concentrations relevant for
397 animal feed applications. It is possible that the TYPLEX® Chelate does not kill these
398 pathogens but reduces their ability to adhere to the gut mucosa and thus lower their
399 chances to compete with beneficial bacteria.
400 The addition of TYPLEX® Chelate to the diet consistently improved broiler AWG
401 and FCR compared to non-supplemented control birds. It has been reported that *C.*
402 *jejuni* can cause a significant decrease in weight gain of poultry (Awad et al., 2014a)
403 and that there is a highly significant association between *Campylobacter* positivity
404 and poorer FCR (Sparks, 2016). *Campylobacter* infection is found to significantly
405 downregulate the gene expression of the sodium/glucose cotransporter (SGLT-1),
406 peptide transporter (PepT-1), glucose transporter (GLUT-2), cationic amino acid
407 transporter (CAT-2), excitatory amino acid transporter (EAAT-3) and the $_{L}$-type
408 amino acid transporter (y^{+}LAT-2) in different parts of the gut (Awad et al., 2014b).
409 Such decreased nutrient absorption not only explains the negative effect of
410 *Campylobacter* colonization on body weight but this could be crucial for the
411 persistence of *Campylobacter* itself. To colonize and invade, *C. jejuni* bacteria require
412 adequate nutrients, mainly amino acids and Ca^{2+} (Fang et al., 2012; Awad et al.,
413 2015). Therefore, reduction in the intestinal uptake of nutrients by an avian host may
414 increase carbon and nitrogen sources that are essential for bacterial growth (Guccione
415 et al., 2008). The present study suggests that TYPLEX® Chelate may also promote
416 growth performance by enhancing intestinal nutrient absorption and reducing

colonization of *C. jejuni*. However, in addition to on-farm environmental conditions and host immune response (Lin, 2009), any negative effects on broiler body weights due to *Campylobacter* could also be strain-specific as different isolates of *C. jejuni* can have different colonization potential (Hermans et al., 2011).

In conclusion, the data from the current studies suggest that TYPLEX® Chelate reduces gut colonization of *C. jejuni* by inhibiting biofilm formation, increases the bacteriostatic effect of VFA and improve intestinal absorptive function. By reducing their adhesion power, it is likely that the spread of *C. jejuni* through other biological and non-biological routes would be reduced. In addition, disabling biofilm resistance may enhance the ability of existing antibiotics to fight infections that are refractory to current treatments and eventually help to reduce human cases of *Campylobacteriosis*.

ACKNOWLEDGEMENT

The work was funded by Akeso Biomedical, Inc., Waltham, MA, USA and the Scottish government (RESAS).

REFERENCES

Allain, V., M. Chemaly, M. J. Laisney, S. Rouxel, S. Quesne, and B. S. Le. 2014. Prevalence of and risk factors for *Campylobacter* colonisation in broiler flocks at the end of the rearing period in France. Br. Poult. Sci. 55:452-459.

Allen, V. M., A. M. Ridley, J. A. Harris, D. G. Newell, and L. Powel. 2011. Influence of production system on the rate of onset of *Campylobacter* colonisation in chicken flocks reared extensively in the United Kingdom. Br. Poult. Sci. 52:30-39.

AOAC. 2006. Official methods of analysis. 18th ed., Assoc. Off. Anal. Chem., Washington, DC.

441 Ashgar, S. S., N. J. Oldfield, K. G. Wooldridge, M. A. Jones, G. J. Irving, D. P.
442 Turner, and D. A. A. Ala'Aldeen. 2007. CapA, an auto transporter protein of
443 *Campylobacter jejuni*, mediates association with human epithelial cells and
444 colonization of the chicken gut. J. Bacteriol. 189:1856–1865.
445 Awad, W. A., J. R. Aschenbach, K. Ghareeb, B. Khayal, C. Hess, and M. Hess.
446 2014b. *Campylobacter* jejuni influences the expression of nutrient transporter
447 genes in the intestine of chickens. Vet. Microbiol. 172:195-201.
448 Awad, W. A., F. Dublecz, C. Hess, K. Dublecz, B. Khayal, J. R. Aschenbach, and M.
449 Hess. 2016. *Campylobacter jejuni* colonization promotes the translocation of
450 *Escherichia coli* to extra-intestinal organs and disturbs the short-chain fatty
451 acids profiles in the chicken gut. Poult. Sci. 95:2259-2265.
452 Awad, W. A., A. Molnár, J. R. Aschenbach, K. Ghareeb, B. Khayal, C. Hess, D.
453 Liebhart, K. Dublecz, and M. Hess. 2014a. *Campylobacter* infection in chickens
454 modulates the intestinal epithelial barrier function. Innate Immun. 21:151-160.
455 Awad, W. A., A. Smorodchenko, C. Hess, J. R. Aschenbach, A. Molnár, and K.
456 Dublecz. 2015. Increased intracellular calcium level and impaired nutrient
457 absorption are important pathogenicity traits in the chicken intestinal epithelium
458 during *Campylobacter jejuni* colonization. Appl. Microbiol. Biotechnol.
459 99:6431–6441.
460 Barrios, P. R., J. Reiersen, R. Lowman, J. R. Bisaillon, P. Michel, V. Fridriksdottir, E.
461 Gunnarsson, N. Stern, O. Berke, S. Mcewen, and W. Martin. 2006. Risk factors
462 for *Campylobacter* species colonisation in broiler flocks in Iceland. Prev. Vet.
463 Med. 74:264-278.

Black, R. E., M. M. Levine, M. L. Clements, T. P. Hughes, and M. J. Blaser. 1988. Experimental *Campylobacter jejuni* infection in humans. J. Infect. Dis. 157:472–479.

Buckley, A. M., J. H. Wang, D. L. Hudson, A. J. Grant, M. A. Jones, D. J. Maskell, and M. P. Stevens. 2010. Evaluation of live-attenuated *Salmonella* vaccines expressing *Campylobacter* antigens for control of *C. jejuni* in poultry. Vaccine. 28:1094-1105.

Buswell, C. M., Y. M. Herlihy, L. M. Lawrence, J. T. McGuiggan, P. D. Marsh, C. W. Keevil, and S. A. Leach. 1998. Extended survival and persistence of *Campylobacter* spp. in water and aquatic biofilms and their detection by immunofluorescent-antibody and -rRNA staining. Appl. Environ. Microbiol. 64:733–741.

Calderon-Gomez, L. I., L. E. Hartley, A. McCormack, D. D. Ringoir, and V. Korolik. 2009. Potential use of characterised hyper-colonising strain(s) of *Campylobacter jejuni* to reduce circulation of environmental strains in commercial poultry. Vet. Microbiol. 134:353-361.

Carrillo, C. L., R. J. Atterbury, A. El-Shibiny, P. L. Connerton, E. Dillon, A. Scott, and I. F. Connerton. 2005. Bacteriophage therapy to reduce *Campylobacter jejuni* colonization of broiler chickens. Appl. Environ. Microbiol. 71:6554-6563.

Cawthraw S. A., and D. G. Newell. 2010. Investigation of the presence and protective effects of maternal antibodies against *Campylobacter jejuni* in chickens. Avian Dis. 54: 86-93.

Chaveerach, P., D. A. Keuzenkamp, L. J. Lipman, and F. Van Knapen. 2004. Effect of organic acids in drinking water for young broilers on *Campylobacter*

infection, volatile fatty acid production, gut microflora and histological cell changes. Poult. Sci. 83:330-334.

Costerton, J. W. 1995. Overview of microbial biofilms. J Ind Microbiol. 15*:*137–140.

Costerton, J. W., P. S. Stewart, and E. P. Greenberg. 1999. Bacterial biofilms: A common cause of persistent infections. Sci. 284:1318-1322.

Duffy, L. L., P. J. Blackall, R. N. Cobbold, and N. Fegan. 2014. Quantitative effects of in-line operations on *Campylobacter* and *Escherichia coli* through two Australian broiler processing plants. Int. J. Food Microbiol. 188:128-134.

EFSA. 2009. Scientific colloquium series of the European Food Safety Authority *N° 12 – December 2008:* Assessing health benefits of controlling *Campylobacter* in the food chain. (4-5 December 2008, Rome, Italy).

www.efsa.europa.eu/sites/default/files/event/colloque081204-m.pdf

EFSA. 2011. Scientific opinion on *Campylobacter* in broiler meat production: control options and performance objectives and/or targets at different stages of the food chain. EFSA J. 9:2105.

Fang, L., Y. Yeshi, W. Yuezhu, D. Bo, D. Y. Hongwei, L. Li, X. Charlie, W. Shengyue, Z. Baoli, and W. Xin. 2012. Higher-Level Production of Volatile Fatty Acids *In Vitro* by Chicken Gut Microbiotas than by Human Gut Microbiotas as Determined by Functional Analyses. Appl. Environ. Microbiol. 78:5763–5772.

Guccione, E., M. R. Leon-Kempis, B. M. Pearson, E. Hitchin, F. Mulholland, P. M. Van Diemen, M. P. Stevens, and D. J. Kelly. 2008. Amino acid-dependent growth of *Campylobacter jejuni*: key roles for aspartase (AspA) under microaerobic and oxygen-limited conditions and identification of AspB (Cj0762), essential for growth on glutamate. Mol. Microbiol. 69:77–93.

514 Hald, T., W. Aspinall, B. Devleesschauwer, R. Cooke, T. Corrigan, and A. H.
515 Havelaar. 2015. World Health Organization estimates of the relative
516 contributions of food to the burden of disease due to selected foodborne
517 hazards: a structured expert elicitation. PLoS ONE. 11:e0145839.
518 Hermans, D., A. Martel, K. Van Deun, M. Verlinden, F. Van Immerseel, A. Garmyn,
519 W. Messens, M. Heyndrickx, F. Haesebrouck, and F. Pasmans. 2010. Intestinal
520 mucus protects *Campylobacter jejuni* in the ceca of colonized broiler chickens
521 against the bactericidal effects of medium-chain fatty acids. Poult. Sci. 89:1144-
522 1155.
523 Hermans, D., K. Van Deun, A. Martel, F. Van Immerseel, W. Messens, M.
524 Heyndrickx, F. Haesebrouck, and F. Pasmans. 2011. Colonization factors of
525 *Campylobacter jejuni* in the chicken gut. Vet. Res. 42:82–96.
526 Joshua, G. W., C. Guthrie-Irons, A. V. Karlyshev, and B. W. Wren. 2006. Biofilm
527 formation in *Campylobacter jejuni*. Microbiol. 152**:**387-396.
528 Kaino, K., H. Hayashidani, K. Kaneko, and M. Ogawa. 1988. Intestinal colonization
529 of *Campylobacter jejuni* in chickens. Japanese J. Vet. Sci. 50:489–494.
530 Kalmokoff, M., P. Lanthier, T. Tremblay, M. Foss, P. Lau, G. Sanders, J. Austin, J.
531 Kelly, and C. M. Szymanski. 2006. Proteomic analysis of *Campylobacter jejuni*
532 11168 biofilms reveals a role for the motility complex in biofilm formation. J.
533 Bacteriol. 188*:*4312–4320.
534 Kazwala, R. R., J. D. Collins, J. Hannan, R. A. Crinion, and H. O'Mahony. 1990.
535 Factors responsible for the introduction and spread of *Campylobacter jejuni*
536 infection in commercial poultry production. Vet. Record. 126:305–306.

Khattak, F., S. Williams, J. Mahdavi, and J. Houdijk. 2017. The effect of TYPLEX Chelate on broiler growth performance, litter coccidial oocysts and caecal microbial profile. Poult. Sci. 96 (E-supplement1):131.

Kubena, L. F., R. H. Bailey, J. A. Byrd, C. R. Yound, D. E. Corrier, L. H. Stanker, and G. E. Rottinghaus. 2001. Cecal volatile fatty acids and broiler chick susceptibility to *Salmonella typhimurium* colonization as affected by aflatoxins and T-2 toxin. Poult. Sci. 80:411–417.

Lehtola, M. J., T. Pitkanen, L. Miebach, and I. T. Miettinen. 2006. Survival of *Campylobacter jejuni* in potable water biofilms: a comparative study with different detection methods. Water Sci. Technol. 54:57–61.

Lin, J. 2009. Novel approaches for *Campylobacter* control in poultry. Foodborne Pathog. Dis. 6:755-765.

Luangtongkum, T., B. Jeon, J. Han, P. Plummer, C. M. Logue, and Q. Zhang. 2009. Antibiotic resistance in *Campylobacter*: emergence, transmission and persistence. Future Microbiol. 4(2):189–200.

Mahdavi, J., N. Pirinccioglu, N. J. Oldfield, E. Carlsohn, J. Stoof, A. Aslam, T. Self, S. A. Cawthraw, L. Petrovska, N. Colborne, C. Sihlbom, T. Borén, K. G. Wooldridge, and D. A. A. Ala'Aldeen. 2014. A novel *O*-linked glycan modulates *Campylobacter jejuni* major outer membrane protein-mediated adhesion to human histo blood group antigens and chicken colonization. Open Biol. 4:130-202.

Miller, W., and R. Mandrell. 2005. Prevalence of *Campylobacter* in the food and water supply: incidence, outbreaks, isolation and detection. *In Campylobacter* Molecular and Cellular Biology *(ed).* Ketley, J., and Konkel, M. 101–163. Norfolk, UK: Horizon.

562 Min, T., M. Vedadi, D. C. Watson, G. A. Wasney, C. Munger, M. Cygler, A. Matte,
563 and N. M. Young. 2009. Specificity of *Campylobacter jejuni* adhesin PEB3 for
564 phosphates and structural differences among its ligand complexes. Biochem.
565 48:3057–3067.
566 Muller, A., R. Leo´n-Kempis Mdel, E. Dodson, K. S. Wilson, A. J. Wilkinson, and D.
567 J. Kelly. 2007. A bacterial virulence factor with a dual role as an adhesin and a
568 solute binding protein: the crystal structure at 1.5 A resolution of the PEB1a
569 protein from the food-borne human pathogen *Campylobacter jejuni*. J. Mol.
570 Biol. 372:160–171.
571 Neal-McKinney, J. M., D. R. Samuelson, T. P. Eucker, M. S. Nissen, R. Crespo, and
572 M. E. Konkel. 2014. Reducing *Campylobacter jejuni* Colonization of Poultry
573 via Vaccination. PLoS ONE. 12:e114254.
574 O'Toole, G. A., and R. Kolter. 1998. Initiation of biofilm formation in *Pseudomonas*
575 *fluorescens* WCS365 proceeds via multiple, convergent signalling pathways: a
576 genetic analysis. Mol. Microbiol. 28:449–461.
577 Rehman, H. U., W. Vahjen, W. A. Awad, and J. Zentek. 2007. Indigenous bacteria
578 and bacterial metabolic products in the gastrointestinal tract of broiler chickens.
579 Arch. Anim. Nutr. 61:319-335.
580 Robyn, J., G. Rasschaert, F. Pasmans, and M. Heyndrickx. 2015. Thermotolerant
581 *Campylobacter* during broiler rearing: risk factors and intervention. Compr.
582 Rev. Food Sci. Food Saf. 14:81-105.
583 Rosenquist, H., N. L. Nielsen, H. M. Sommer, B. Norrung, and B. B. Christensen.
584 2003. Quantitative risk assessment of human *Campylobacteriosis* associated
585 with thermophilic *Campylobacter* species in chickens. Int. J. Food Microbiol.
586 83:87–103.

587 Ruiz-Palacios, G. M. 2007. The health burden of *Campylobacter* infection and the
588 impact of antimicrobial resistance: Playing chicken. Clin. Infect. Dis. 44:701-
589 703.
590 Sahin, O., Kassem II, Z. Shen, J. Lin, G. Rajashekara, and Q. Zhan. 2015.
591 *Campylobacter* in Poultry: Ecology and Potential Interventions. Avian Dis.
592 59:185-200.
593 Sahin, O., N. Luo, S. Huang, and Q. Zhang, 2003. Effect of *Campylobacter*-specific
594 maternal antibodies on *Campylobacter jejuni* colonization in young chickens.
595 Appl. Environ. Microbiol. 69:5372-5379.
596 Sanders, S. Q., J. F. Frank, and J. W. Arnold. 2008. Temperature and nutrient effects
597 on *Campylobacter jejuni* attachment on multispecies biofilms on stainless steel.
598 J. Food Prot. 71:271–278.
599 Sparks, N. 2016. On-farm control of *Campylobacter*. In 27th Ann. Aust. Poult. Sci.
600 Symposium: 125.
601 Stepanovic, S., D. Vukovic, I. Dakic, B. Savic, and Svabic-VM. 2000. A modified
602 microtiter-plate test for quantification of staphylococcal biofilm formation. J.
603 Microbiol. Methods. 40, Issue 2:175-179.
604 Stewart, P. S. 2002. Mechanisms of antibiotic resistance in bacterial biofilms, Int. J.
605 Med. Microbiol. 292:107-113.
606 Stoodley, L. H., J. W. Costerton, and P. L. Stoodley. 2004. Bacterial biofilms: from
607 the natural environment to infectious diseases. Nat. Rev. Microbiol. 2:95-108.
608 Sulaeman, S., G. Le Bihan, A. Rossero, M. Federighi, E. Dé, and O. Tresse. 2010.
609 Comparison between the biofilm initiation of *Campylobacter jejuni* and
610 *Campylobacter coli* strains to an inert surface using BioFilm Ring Test®. J.
611 Appl. Microbiol. 108:1303–1312.

612 Sun, Y., and M. X. O'Riordan. 2013. Regulation of bacterial pathogenesis by
613 intestinal short-chain fatty acids. Adv. Appl. Microbiol. 85:93.
614 Sunkara, L. T., W. Jiang, and G. Zhang. 2012. Modulation of antimicrobial host
615 defence peptide gene expression by free fatty acids. PloS ONE. 7(11):e49558.
616 Svetoch, E. A., and N. J. Stern. 2010. Bacteriocins to control *Campylobacter spp*. in
617 poultry – a review. Poult. Sci. 89:1763-1768.
618 Trachoo, N., and J. Frank. 2002. Effectiveness of chemical sanitizers against
619 *Campylobacter jejuni*-containing biofilms. J. Food Prot. 65:1117–1121.
620 Umar, S., A. Maiyah, and A. Mushtaq. 2016. *Campylobacter* infections in poultry:
621 Update on challenges and potential immune interventions. World's Poult. Sci. J.
622 72:381-390.
623 Van Der, W. P. W., S. Biesterveld, S. Notermans, H. Hofstra, B. A. P. Urlings, and F.
624 Van Knapen. 2000. Role of volatile fatty acids in development of the cecal
625 microflora in broiler chickens during growth. Appl. Environ. Microbiol.
626 66:2536-2540.
627 Wagenaar, J. A., D. J. Mevius, and A. H. Havelaar. 2006. *Campylobacter* in primary
628 animal production and control strategies to reduce the burden of human
629 *Campylobacteriosis*. Rev. Sci. Tech. 25:581–594.
630 Wagenaar, J. A., M. A. P. Van Bergen, M. A. Mueller, T. M. Wassenaar, and R. A.
631 Carlton. 2005. Phage therapy reduces *Campylobacter jejuni* colonization in
632 broilers. Vet. Microbiol. 109:275-283.
633 WHO. 2013. The global review of *Campylobacteriosis* (Report of expert consultation,
634 Utrecht, The Netherlands. 9-11 July 2012)
635 www.who.int/iris/bitstream/10665/80751/1/9789241564601_eng.pdf
636

637 **Table 1.** Composition of basal diets

Ingredients (% unless otherwise stated)	Starter diets (d 0-21)	Grower diets (d 21-42)
Barley	10.415	8.315
Wheat	50	55
Soya Ext Hipro	26	23
Full fat Soya Cherwell	5	5
L Lysine HCl	0.4	0.3
DL-methionine	0.4	0.35
L-threonine	0.15	0.15
Soya Oil	4	4.5
Limestone Trucal 52	1.25	1.25
Monocalcium phosphate	1.5	1.25
Salt	0.25	0.25
Sodium bicarbonate	0.15	0.15
Broiler Premix*	0.4	0.4
Robenz 66G Premix (robenidine coccidiostat)	0.05	0.05
Ronozyme WX (polysaccharidase enzymes	0.02	0.02
Ronozyme P 5000 (CT) (phytase enzymes)	0.015	0.015
Total	100%	100%
Calculated analysis		
Fat (ether extract)	6.39	6.85
Protein	21.84	20.64
Fibre	3.08	3.02
Ash	6.02	5.68
ME-P	12.73	13.04
Total lysine	1.43	1.28
Available lysine	1.33	1.19
Methionine	0.69	0.62
Total methionine and cysteine	1.03	0.95
Threonine	0.91	0.86
Tryptophan	0.25	0.23
Calcium	0.95	0.91
Phosphorus	0.73	0.66
Available phosphorus	0.48	0.42
Sodium chloride	0.30	0.30

Sodium	0.17	0.17
Analysed Nutrient composition		
Dry Matter	88.1	88.2
Crude protein†	21.8	20.7
Ether extract	6.66	7.12
Iron (mg/kg)	135	99

*Premix provided per kg: vitamin A, 2400 IU; vitamin D3, 1000 IU; vitamin E, 10,000 IU; vitamin K3, 600 mg/kg; vitamin B1, 400 mg/kg; vitamin B2, 1,400 mg/kg; pantothenic acid, 3,000 mg/kg; nicotinic acid, 10,000 mg/kg; vitamin B6, 1,000 mg/kg; vitamin B12, 3,000 ug/kg; folic acid: 200 mg/kg; biotin: 40 mg/kg; copper, 2,000 mg/kg; zinc, 16,000 mg/kg; manganese, 20,000 mg/kg; iodine , 200 mg/kg; selenium, 40 mg/kg; choline choride, 500 g: No added iron in premix.

† Crude protein = Nitrogen x 6.25.

645 **Table 2.** Calculated and analysed value of TYPLEX® Chelate in experimental diets.

Treatment	Calculated Value	Analysed Value of TYPLEX® Chelate in starter diets (g/kg)	Analysed Value of TYPLEX® Chelate in grower diets (g/kg)
T_1	0	0	0
T_2	0.02	0.02	0.02
T_3	0.05	0.06	0.04
T_4	0.20	0.19	0.26

646

647 **Table 3.** Inhibitory effect of TYPLEX® Chelate on *C. jejuni* (NCTC11168) biofilm
648 formation using plastic beads.
649

Treatment	Starter diet Log_{10} cfu/ml	Grower diet Log_{10} cfu/ml
T1	5.608	5.573
T2	5.082	5.194
T3	5.285	4.129
T4	5.123	4.583
SEM	0.040	0.076
P-value's for contrast		
T1 versus T2	<0.001	<0.001
T1 versus T3	<0.001	<0.001
T1 versus T4	<0.001	<0.001
Linear	<0.001	

650 N°. replicates/treatment = 18; cfu = colony forming units.

651 SEM = standard error of the mean.

652 T1= Control ((HCl/KCl) ; T2 = 0.02 g/kg TYPLEX® Chelate ;T3 = 0.05 g/kg TYPLEX®

653 Chelate; T4 = 0.20 g/kg TYPLEX® Chelate.

Table 4. Effect of dietary treatments on growth performance of broilers[1]

	Starter phase (d 0-21)			Grower phase (d 21-39)			Overall Performance (d0-39)		
Item	AWG[2] (kg/bird)	AFI[3] (kg/bird)	FCR[4] (kg/kg)	AWG (kg/bird)	AFI (kg/bird)	FCR (kg/kg)	AWG (kg/bird)	AFI (kg/bird)	FCR (kg/kg)
Treatment									
T1	0.773	1.077	1.400	0.381	2.948	1.611	2.618	4.025	1.544
T2	0.821	1.076	1.314	0.428	2.915	1.579	2.695	3.991	1.495
T3	0.776	1.024	1.327	0.461	2.865	1.533	2.660	3.890	1.471
T4	0.829	1.085	1.316	0.479	2.943	1.543	2.748	4.028	1.472
SEM	0.014	0.016	0.027	0.020	0.036	0.023	0.029	0.047	0.016
P-values for contrast[5]									
T1 versus T2	0.002	0.979	0.004	0.027	0.361	0.182	0.02	0.484	0.007
T1 versus T3	0.842	0.003	0.012	<0.001	0.031	0.002	0.181	0.009	<0.001
T1 versus T4	<0.001	0.584	0.005	<0.001	0.889	0.007	<0.001	0.94	<0.001
Linear	0.011	0.614	0.010	0.579	0.579	0.002	0.001	0.559	<0.001

[1]All means are average of 10 pens per treatment.
[2] AWG = Average weight gain.
[3] AFI = Average feed intake.
[4] FCR = Feed conversion ratio.
T1= Control; T2 = 0.02 g/kg TYPLEX® Chelate; T3 = 0.05 g/kg TYPLEX® Chelate; T4 = 0.20 g/kg TYPLEX® Chelate.
[5]Significance level ($P \leq 0.05$).

Table 5. Caecal microbial counts at 42 days of age [1]

Treatment	*Campylobacter* spp.[1]	*E. coli*[1]
	log10 cfu/g	log10 cfu/g
T1	5.86	7.83
T2	5.03	7.24
T3	3.81	7.05
T4	3.74	6.64
SEM	0.296	0.191
P-values for contrast[2]		
1 vs 2	0.005	0.002
1vs 3	<0.001	<0.001
1vs 4	<0.001	<0.001
Linear	<0.001	<0.001

[1]All means are average of 20 (2 x culture plates/treatment). *Campylobacter* spp. cultured on CCDA medium, *E. coli* cultured on chromogenic agar; CFU = colony forming unit; SEM = standard error of the mean;
T1= Control; T2 = 0.02 g/kg TYPLEX® Chelate; T3 = 0.05 g/kg TYPLEX® Chelate; T4 = 0.20 g/kg TYPLEX® Chelate
[2]Significant level ($P \leq 0.05$).

669 **Table 6.** Effect of experimental diets on the concentrations of volatile fatty acid
670 (VFA; mg/kg) in the caecal content of broilers at 42 d of age.
671

Item	Acetic Acid	n-Butyric Acid	Propionic Acid	n-Valeric acid	Iso Valeric Acid	Iso Butyric Acid	Total VFA†
Treatment							
T_1	4785	1222	1048	179	214	126	7573
T_2	6009	2139	1232	228	212	135	9954
T_3	5979	2032	1199	255	310	175^{b}	9567
T_4	5497	1728	1155	237	256	144^{ab}	9018
SEM	387.9	188.9	95.2	30.3	37	18.09	622.4
P values for contrast[1]							
1 versus 2	0.003	<0.001	0.059	0.115	0.965	0.635	<0.001
1 versus 3	0.003	<0.001	0.118	0.015	0.012	0.009	0.002
1 versus 4	0.072	0.010	0.266	0.062	0.252	0.331	0.024
Linear	0.091	0.022	0.342	0.040	0.058	0.108	0.050

672 Means represents 2 birds per pen and 10 pens /treatment.
673 [1]Significance level ($P \leq 0.05$).
674 SEM = Standard error of differences of means.
675 †Total VFA = sum of all individual volatile fatty acid (VFA).